Work

Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.8035

Authors: Robert M. Rifkin, Jason M. Melear, Edward Faber, William I. Bensinger, John M. Burke, Mohit Narang, Don A. Stevens, Kathleen Gray, Yana Lutska, Padma Bobba, Keqin Qi, Ming Qi, Thomas S. Lin, Habte Aragaw Yimer

Institutions: Rocky Mountain Cancer Centers, Texas Oncology, Oncology Hematology Care, Maryland Oncology Hematology, Norton Healthcare, Janssen Scientific Affairs (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Janssen Research and Development

OpenAlex ID: W3171007561

Cites:

Cited by:

Related to: 10